NervGen Pharma Ownership

Stocks . Canada . 
Stock . NervGen Pharma Corp
NGEN Stock  CAD 2.88  0.01  0.35%   
NervGen Pharma Corp maintains a total of 70.31 Million outstanding shares. NervGen Pharma Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2018-03-31
Previous Quarter
59.2 M
Current Value
59.4 M
Avarage Shares Outstanding
38.3 M
Quarterly Volatility
13.3 M
 
Covid
Some institutional investors establish a significant position in stocks such as NervGen Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of NervGen Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is likely to drop to -83.88 in 2024. Common Stock Shares Outstanding is likely to drop to about 41.5 M in 2024. Net Loss is likely to climb to about (17.7 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NervGen Pharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

NervGen Stock Ownership Analysis

About 23.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.38. NervGen Pharma Corp had not issued any dividends in recent years. NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange. To find out more about NervGen Pharma Corp contact Michael Kelly at 778 731 1711 or learn more at https://www.nervgen.com.

NervGen Pharma Outstanding Bonds

NervGen Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NervGen Pharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NervGen bonds can be classified according to their maturity, which is the date when NervGen Pharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp Bond
US235822AB96		View
Boeing Co 2196 Corp Bond
US097023DG73		View
BNP Paribas FRN Corp Bond
USF1R15XK367		View
AerCap Global Aviation Corp Bond
US00773HAA59		View

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NervGen Stock Analysis

When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY